End Cash: The amount of cash held by the company for the given period.
Innate Pharma SA (IPHYF) had End Cash of $71.85M for the most recently reported fiscal quarter, ending 2024-12-31.
| Income Statement Financials | |
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
| Balance Sheet Financials | |
$92.78M |
|
-- |
|
$21.84M |
|
$120.18M |
|
$35.69M |
|
-- |
|
$74.93M |
|
$110.62M |
|
$9.56M |
|
$9.56M |
|
$9.56M |
|
-- |
|
| Cash Flow Statement Financials | |
$-7.46M |
|
$9.96M |
|
$-6.50M |
|
$76.40M |
|
|
End Cash |
$71.85M |
$-4.55M |
|
-- |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|